372 Evolving Patterns in Clinical Utilization of Stereotactic Laser Ablation (SLA): An Analysis of the Multi-center Prospective Registry LAANTERN

Neurosurgery ◽  
2017 ◽  
Vol 64 (CN_suppl_1) ◽  
pp. 287-288
Author(s):  
Clark C Chen ◽  
Robert Rennert ◽  
Usman Khan ◽  
Stephen B Tatter ◽  
Melvin Field ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Laser Ablation ◽  
Invasive Procedure ◽  
Primary Brain Tumor ◽  
Low Grade ◽  
Newly Diagnosed ◽  
Minimally Invasive Procedure ◽  
Tumor Patients ◽  
Clinical Utilization ◽  
Neurosurgical Patients

Abstract INTRODUCTION Stereotactic laser ablation (SLA) is a minimally invasive procedure that is increasingly utilized in neurosurgery. We wished to understand how this procedure is changing the landscape of treatment option for neurosurgical patients. METHODS Patients undergoing stereotactic laser ablation were prospectively enrolled in the LAANTERN registry. Data from the first 100 enrolled patients are presented here. RESULTS >Clinical indications for SLA include treatment of high grade gliomas (HGG, 40%), brain metastases (BM, 34%), epilepsy (17%), low grade gliomas (5%), and meningioma/other primary brain tumor (4%). For HGGs, SLA was equally likely used in the up-front (45%) or the recurrent setting (55%, P = 0.54). In contrast, SLA was predominantly used as treatment for BMs that failed radiation therapy/radiosurgery (91%), with only 9% of SLAs performed as up-front treatment for newly diagnosed lesions (P < 0.001). Of all SLAs performed in brain tumor patients, 42.9% of the procedures were performed in lieu of surgical resection, and 21% were performed because the lesion was not accessible through conventional neurosurgery. Time trend analysis comparing the first and the latter cohort of 50 enrolled patient revealed expanding oncologic applications of SLA beyond treatment of HGG and BM (P = 0.02). CONCLUSION HGGs and BMs are the leading indications for SLA in the LAANTERN study. For HGGs, SLA is equally likely used in the up-front or recurrent setting. For BMs, SLA is typically used in the recurrent setting. There is an evolving trend toward expanding oncologic applications of SLA beyond treatment of HGGs and BMs

Swallowing assessment in primary brain tumor patients with dysphagia

Neurology ◽  
1994 ◽  
Vol 44 (10) ◽  
pp. 1927-1927 ◽  
Author(s):  
H. B. Newton ◽  
C. Newton ◽  
D. Pearl ◽  
T. Davidson
Keyword(s):  
Brain Tumor ◽  
Primary Brain Tumor ◽  
Tumor Patients ◽  
Swallowing Assessment

scholarly journals Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis

CNS Oncology ◽  
2021 ◽  
pp. CNS77
Author(s):  
Jennifer H Kang ◽  
Christa B Swisher ◽  
Evan D Buckley ◽  
James E Herndon ◽  
Eric S Lipp ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Brain Tumor ◽  
Hematological Malignancies ◽  
Descriptive Analysis ◽  
Primary Brain Tumor ◽  
Icu Mortality ◽  
Tumor Patients ◽  
Common Indication ◽  
Better Than

Purpose: To describe our population of primary brain tumor (PBT) patients, a subgroup of cancer patients whose intensive care unit (ICU) outcomes are understudied. Methods: Retrospective analysis of PBT patients admitted to an ICU between 2013 to 2018 for an unplanned need. Using descriptive analyses, we characterized our population and their outcomes. Results: Fifty-nine PBT patients were analyzed. ICU mortality was 19% (11/59). The most common indication for admission was seizures (n = 16, 27%). Conclusion: Our ICU mortality of PBT patients was comparable to other solid tumor patients and the general ICU population and better than patients with hematological malignancies. Further study of a larger population would inform guidelines for triaging PBT patients who would most benefit from ICU-level care.

IMMU-14. REVEALING THE MANY MYELOID STATES IN HUMAN BRAIN TUMORS AND WAYS TO PERTURB THEM

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi94-vi95
Author(s):  
Tyler Miller ◽  
Chadi El Farran ◽  
Julia Verga ◽  
Charles Couturier ◽  
Zeyu Chen ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Tumor Microenvironment ◽  
Immune Cells ◽  
Ex Vivo ◽  
Myeloid Cells ◽  
Human Tumor ◽  
Myeloid Cell ◽  
Low Grade ◽  
Tumor Patients ◽  
The Many

Abstract Recent breakthroughs in immunotherapy have revolutionized treatment for many types of cancer, but unfortunately trials of these therapies have failed to provide meaningful life-prolonging benefit for brain tumor patients, potentially due to abundant immunosuppressive myeloid cells in the tumor. Our ultimate goal is to reprogram immunosuppressive tumor associated myeloid cells to an antitumor state to enable effective immunotherapy. Towards this goal, we have deeply characterized the immune microenvironment of more than 50 primary high and low grade gliomas using high-throughput single-cell RNA-sequencing to reveal recurrent myeloid cell states and immunosuppressive programs across IDH1 wild-type and mutant tumors. We have also established a brain tumor organoid model from primary patient tissue that maintains all of the tumor microenvironment, including myeloid and other immune cells. We utilize the this model to functionally test data-driven reprogramming strategies and understand how they impact the states of tumor and immune cells in the ex vivo human tumor microenvironment.

scholarly journals QLIF-41. UNDERSTANDING EMOTIONAL DISTRESS IN PRIMARY BRAIN TUMOR PATIENTS: IS THERE A RELATIONSHIP WITH FEAR OF DEATH?

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi210-vi210
Author(s):  
Ashlee Loughan ◽  
Sarah Braun
Keyword(s):  
Brain Tumor ◽  
Emotional Distress ◽  
Primary Brain Tumor ◽  
Fear Of Death ◽  
Tumor Patients

Gender difference in relation to depression and quality of life among patients with a primary brain tumor

2006 ◽  
Vol 21 (3) ◽  
pp. 194-199 ◽  
Author(s):  
Arja Mainio ◽  
Helinä Hakko ◽  
Asko Niemelä ◽  
John Koivukangas ◽  
Pirkko Räsänen
Keyword(s):  
Quality Of Life ◽  
Brain Tumor ◽  
Functional Status ◽  
Primary Brain Tumor ◽  
Karnofsky Performance Scale ◽  
Tumor Patients ◽  
The Relationship ◽  
Depressive Patients ◽  
Performance Scale

AbstractObjective. –We studied the relationship between depressive symptoms and quality of life (QOL) as well as functional status in primary brain tumor patients at recurrent measurements. Differences in QOL between depressive and non-depressive samples by gender were controlled for tumor characteristics and patients' psychosocial factors.Materials and methods. –The data consisted of 77 patients with a primary brain tumor, 30 males and 47 females. Depression of the patients was assessed by Beck Depression Inventory (BDI) and Crown-Crisp Experiential Index (CCEI), functional status by Karnofsky Performance scale (KPS) and QOL by Sintonen's 15D before tumor operation as well as at 3 months and at 1 year from surgical operation of the tumor.Results.The level of QOL in females was lower compared to that of males. Depression was the main predictor for worse QOL in the patients at all measurements. Depressive patients with a benign brain tumor had significantly worse QOL versus non-depressive ones.Discussion and conclusion. –Decreased QOL was strongly related to depression, especially among patients with a benign brain tumor. Further studies are needed to find whether sufficient depression therapy improves the QOL of patients.

scholarly journals Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors

Cancers ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 1546 ◽  
Author(s):  
Alena Kopkova ◽  
Jiri Sana ◽  
Tana Machackova ◽  
Marek Vecera ◽  
Lenka Radova ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Brain Tumor ◽  
Brain Tumors ◽  
Low Grade ◽  
Tumor Type ◽  
Tumor Patients ◽  
Primary Tumors ◽  
Mirna Profiling ◽  
Tumor Types ◽  
Cns Malignancies

Central nervous system (CNS) malignancies include primary tumors that originate within the CNS as well as secondary tumors that develop as a result of metastatic spread. Circulating microRNAs (miRNAs) were found in almost all human body fluids including cerebrospinal fluid (CSF), and they seem to be highly stable and resistant to even extreme conditions. The overall aim of our study was to identify specific CSF miRNA patterns that could differentiate among brain tumors. These new biomarkers could potentially aid borderline or uncertain imaging results onto diagnosis of CNS malignancies, avoiding most invasive procedures such as stereotactic biopsy or biopsy. In total, 175 brain tumor patients (glioblastomas, low-grade gliomas, meningiomas and brain metastases), and 40 non-tumor patients with hydrocephalus as controls were included in this prospective monocentric study. Firstly, we performed high-throughput miRNA profiling (Illumina small RNA sequencing) on a discovery cohort of 70 patients and 19 controls and identified specific miRNA signatures of all brain tumor types tested. Secondly, validation of 9 candidate miRNAs was carried out on an independent cohort of 105 brain tumor patients and 21 controls using qRT-PCR. Based on the successful results of validation and various combination patterns of only 5 miRNA levels (miR-30e, miR-140, let-7b, mR-10a and miR-21-3p) we proposed CSF-diagnostic scores for each tumor type which enabled to distinguish them from healthy donors and other tumor types tested. In addition to this primary diagnostic tool, we described the prognostic potential of the combination of miR-10b and miR-196b levels in CSF of glioblastoma patients. In conclusion, we performed the largest study so far focused on CSF miRNA profiling in patients with brain tumors, and we believe that this new class of biomarkers have a strong potential as a diagnostic and prognostic tool in these patients.

Symmetry of the arcuate fasciculus and its impact on language performance of patients with brain tumors in the language-dominant hemisphere

2017 ◽  
Vol 127 (6) ◽  
pp. 1407-1416 ◽  
Author(s):  
Margit Jehna ◽  
Juliane Becker ◽  
Karla Zaar ◽  
Gord von Campe ◽  
Kariem Mahdy Ali ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Fiber Tracking ◽  
Low Grade ◽  
High Grade ◽  
Arcuate Fasciculus ◽  
Language Performance ◽  
Language Deficits ◽  
Tumor Patients ◽  
Eloquent Areas ◽  
The Right

OBJECTIVECerebral damage in frontal, parietal, and temporal brain areas and, probably more importantly, their interconnections can lead to deficits in language. However, neural plasticity and repair allow the brain to partly compensate for neural injury, mediated by both functional and structural changes. In this study, the authors sought to systematically investigate the relationship between language performance in brain tumor patients and structural perisylvian pathways (i.e., the arcuate fasciculus [AF]) using probabilistic fiber tracking on diffusion tensor imaging. The authors used a previously proposed model in which the AF is divided into anterior, long, and posterior segments. The authors hypothesized that right-handed patients with gliomas in the language-dominant (left) hemisphere would benefit from a more symmetrical or right-lateralized language pathway in terms of better preservation of language abilities. Furthermore, they investigated to what extent specific tumor characteristics, including proximity to the AF, affect language outcome in such patients.METHODSTwenty-seven right-handed patients (12 males and 15 females; mean age 52 ± 16 years) with 11 low-grade and 16 high-grade gliomas of the left hemisphere underwent 3-T diffusion-weighted MRI (30 directions) and language assessment as part of presurgical planning. For a systematic quantitative evaluation of the AF, probabilistic fiber tracking with a 2 regions of interest approach was carried out. Volumes of the 3 segments of both hemispheric AFs were evaluated by quantifying normalized and thresholded pathways. Resulting values served to generate the laterality index of the AFs.RESULTSPatients without language deficits tended to have an AF that was symmetric or lateralized to the right, whereas patients with deficits in language significantly more often demonstrated a left-lateralized posterior segment of the AF. Patients with high-grade gliomas had more severe language deficits than those with low-grade gliomas. Backward logistic regression revealed the laterality index of the posterior AF segment and tumor grade as the only independent statistically significant predictors for language deficits in this cohort.CONCLUSIONSIn addition to the well-known fact that tumor entity influences behavioral outcome, the authors' findings suggest that the right homologs of structural language-associated pathways could be supportive for language function and facilitate compensation mechanisms after brain damage in functionally eloquent areas. This further indicates that knowledge about preoperative functional redistribution (identified by neurofunctional imaging) increases the chance for total or near-total resections of tumors in eloquent areas. In the future, longitudinal studies with larger groups are mandatory to overcome the methodological limitations of this cross-sectional study and to map neuroplastic changes associated with language performance and rehabilitation in brain tumor patients.

Somatization Symptoms Are Related to Right-Hemispheric Primary Brain Tumor: A Population-Based Prospective Study of Tumor Patients in Northern Finland

2009 ◽  
Vol 50 (4) ◽  
pp. 331-335 ◽  
Author(s):  
Arja Mainio ◽  
Helinä Hakko ◽  
Asko Niemelä ◽  
John Koivukangas ◽  
Pirkko Räsänen
Keyword(s):  
Brain Tumor ◽  
Prospective Study ◽  
Population Based ◽  
Primary Brain Tumor ◽  
Tumor Patients

scholarly journals Input of molecular analysis in medical management of primary brain tumor patients

2015 ◽  
Vol 171 (6-7) ◽  
pp. 457-465
Author(s):  
A. Idbaih ◽  
A. Duran-Peña ◽  
C. Bonnet ◽  
F. Ducray
Keyword(s):  
Brain Tumor ◽  
Molecular Analysis ◽  
Medical Management ◽  
Primary Brain Tumor ◽  
Tumor Patients
Sign in / Sign up

Export Citation Format

Share Document